Nemotis 150, 1 Strip

Nemotis tablet is indicated in the treatment of the following infections:

• Lower respiratory tract infections: acute bronchitis, pneumonia, pulmonary suppuration.
• Ear, nose, and throat (ENT) infections: otitis externa, tympanitis, sinusitis.
• Genitourinary infections: pyelonephritis, cystitis, prostatitis, seminal gland inflammation.
• Upper respiratory tract infections: pharyngitis, tonsillitis.
• Skin and skin structure infections: pustular acne, folliculitis, contagious impetigo, erysipelas, lymphangitis, suppurative nail inflammation, subcutaneous abscess, hidradenitis (sweat gland inflammation), infective sebaceous cyst, chronic pyoderma, secondary infection of external wounds or surgical wounds.
• Gynecological infections: adnexitis, Bartholin gland inflammation.

Upper respiratory tract infections: 150 mg t.i.d., can be increased to 200 mg t.i.d.
ENT infections: 200 mg t.i.d., can be increased to 300 mg t.i.d.
Lower respiratory tract infections: 200 mg t.i.d., can be increased to 300 mg t.i.d.
Skin and skin structure infections: 150 mg t.i.d., can be increased to 200 mg t.i.d.
Genitourinary infections: 200 mg t.i.d., can be increased to 300 mg t.i.d.
Gynecological infections: 150 mg t.i.d., can be increased to 200 mg t.i.d.

1. Imipenem and Cilastatin sodium combination: It has been reported that in animal studies (rat), the concentration of Nemotis in the blood increases. This is due to the obstruction of metabolic fermentation by cilastatin.
2. Furosemide: It has been reported in animal studies (dog), that the kidney toxicity of Nemotis increases.
    
3. Sodium valproate: It has been reported that due to joint use with carbapenem drugs (meropenem, panipenem and imipenem-cilastatin sodium) the concentration of valproic acid in the blood reduces, and there is a recurrence of epileptic fits.

Faropenem is contraindicated in patients with known hypersensitivity to any of the components of this product or to other drugs in the same class, or in patients who have demonstrated anaphylactic reactions to beta-lactams.

Common side effects of Nemotis are Headache, Nausea, Vomiting, Stomach pain, and diarrhea

Safety regarding therapy during pregnancy has not been established. In pregnant women or expectant mothers, the medicine should be given only if the benefit of the treatment is greater than the risks involved. Faropenem is excreted in human milk. Therefore, Faropenem should be given to nursing mothers only if the benefits outweigh the risks.

Nemotis should be administered with caution in the following:

• Patients with a history of hypersensitivity to penicillin, cephem, or carbapenem drugs.
• Patients with a family history of atopy.
• Patients with renal impairment. The dosage should be reduced, or the interval between doses should be increased.
• Geriatric patients.
• Patients with poor oral intake or poor general state (since there are cases that show symptoms of vitamin K deficiency, proper monitoring should be done).

Renal Impairment: In patients with renal impairment, it was found that the plasma concentrations of the drug are increased, and the half-life is extended.

Geriatric Use: The half-life of Nemotis is prolonged in the elderly, and this may be due to a decline in kidney function, which results in high plasma concentrations. Therefore, in the elderly, start with a dose of 150 mg and monitor the patient for any undesirable effects. If diarrhea and loose bowel movements appear, stop the medicine, monitor correctly, and take appropriate measures. There is a tendency for hemorrhage due to vitamin K deficiency in the elderly.

Store Nemotis at room temperature between 20°C and 25°C in its original package. Safely throw away any Nemotis that is out of date or no longer needed. Keep Nemotis and all medicines out of the reach of children. Protect from moisture.